Search

News AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa

At the latest annual congress of the American Academy of Dermatology (AAD), held March 17-22, 2023 in New Orleans, the results of the phase III BE HEARD I and II studies were presented among late-breaking presentations. The studies demonstrate the safety and high efficacy of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa (HS).

Source: Psoriasis 7. 4. 2023

News What to add to amlodipine when it alone is not enough for hypertension?

Treating hypertension is a daily task for not only general practitioners and cardiologists. Polish doctors evaluated the effect of adding bisoprolol on the blood pressure of patients with inadequately controlled hypertension on amlodipine monotherapy in a placebo-controlled AMCOR study.

Source: Cardiovascular Continuum 18. 3. 2024

News Clinical and Microbiological Effect of L. reuteri in the Treatment of Chronic Periodontitis

The Journal of Clinical Periodontology published the results of a study evaluating the effect of the probiotic bacterial strain Lactobacillus reuteri as an adjunctive treatment for chronic periodontitis.

Source: GI, colic and microbiome 6. 4. 2022

News How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients

Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They affect both specific and nonspecific immunity and are classified accordingly. The care for patients with antibody production disorders and hereditary angioedema (HAE) is economically the most demanding and relatively specific. Can a specialized registry help improve this care?

Source: Hereditary Angioedema 3. 1. 2022

News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia

One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.

Source: Chronic Lymphocytic Leukemia 10. 8. 2021

News No deficiency of essential fatty acids in home parenteral nutrition

A Dutch-British study, the results of which were published in the Journal of Parenteral and Enteral Nutrition, addressed the issue of potential deficiency of essential fatty acids in patients using home parenteral nutrition.

Source: Parenteral Nutrition 4. 10. 2021

News Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS

The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). We summarize the current knowledge on its mechanism of action and the results of available studies evaluating its efficacy and safety.

Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News Memantine, Acetylcholinesterase Inhibitors, and Their Combination in the Treatment of Alzheimer's Disease −⁠ Findings from Meta-Analyses

Is memantine, an acetylcholinesterase inhibitor (donepezil), or their combination more advantageous in the therapy of Alzheimer's disease? Two meta-analyses tried to answer this question, and we summarize their conclusions in the following article.

Source: Cognitive in the treatment of Alzheimer's disease 12. 1. 2023

News Prevalence of Depression, Anxiety, and Stress in the Global Population During the COVID-19 Pandemic

A cross-sectional study assessed the prevalence and rate of depression, anxiety, and stress among individuals from various countries around the world during the ongoing COVID-19 pandemic and initial measures to combat the spread of the infection. The impacts on individual subgroups of the population were also analyzed.

Source: Depression and Anxiety 30. 3. 2021

Články časopisu Idiopathic pulmonary fibrosis –⁠ changes in diagnostics and treatment

Author of the article: Vašáková M. Source: Kardiologická revue – Interní medicína | 3/2019 30. 9. 2019

News Pharmacotherapy of Glaucoma in a Nutshell According to the Latest Recommendations of the European Glaucoma Society

The European Glaucoma Society published its latest, 5th version of recommendations for the treatment of glaucoma in 2021. The following text, based on these recommendations, focuses in a nutshell on the basic principles of pharmacotherapy for this disease according to current knowledge.

Source: Treatment of Glaucoma 18. 5. 2023

News What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?

How has the life of patients who now have the opportunity to treat diabetes mellitus in general practice changed? And what do the current prescription conditions for modern antidiabetics bring to their treating physicians? We discuss this and more with diabetologist MUDr. Katarína Nováková.

Source: Modern Treatment of Diabetes with GLP-1 Analogues 21. 6. 2024

News Mechanisms Connecting Diabetes Mellitus and Obesity

Obesity has a close relationship with insulin resistance and diabetes mellitus (DM); weight gain is associated with a higher incidence of both type 1 and type 2 DM. In the development of type 2 DM, depletion of pancreatic β-cells plays a crucial role, which can no longer produce sufficient insulin to maintain glucose homeostasis. The development of diabetes is much more likely if β-cell failure is accompanied by increased insulin resistance. In obese patients, there is a higher proportion of unsaturated fatty acids, glycerol, pro-inflammatory cytokines, hormones, and other substances in the blood, which have a fundamental impact on insulin resistance.

Source: Diabetes 29. 3. 2020

News CASE STUDIES on the topic of progressing interstitial lung processes

This page serves as a hub for case studies on the topic of progressing interstitial processes. The case studies aim to provide a multidisciplinary view on the rare disease topic of IPP.

Source: Progressive Interstitial Pulmonary Processes 7. 2. 2023

News Simple antiemetic prophylaxis for breast cancer patients treated with AC chemotherapy

The combination of an anthracycline cytostatic agent with cyclophosphamide (AC) is among the highly effective chemotherapy regimens for breast cancer. Individually, these cytostatic agents carry a moderate risk of emetogenicity; however, when combined, they are considered to be at high risk of emesis. The recommended prophylaxis involves administering a 5-HT3 serotonin receptor antagonist in combination with an NK1 neurokinin receptor antagonist and the corticosteroid dexamethasone.

Source: Antiemetic Therapy 23. 9. 2020